期刊文献+

新生儿Kasabach—Merritt综合征17例临床分析 被引量:4

Clinical analysis of 17 cases of neonatal Kasabach-Merritt syndrome
原文传递
导出
摘要 目的探讨新生儿Kasabach-Merdtt综合征(Kasabach.Merrittsyndrome,KMS)的临床特点与治疗方法。方法对2007年1月至2012年1月广州市妇女儿童医疗中心新生儿病区的17例KMS患儿l临床资料进行回顾性分析。结果17例中,男13例,女4例,年龄17h一28d,内脏血管瘤4例,皮肤表面血管瘤13例,入院时均有血小板减少及凝血功能异常。17例首先接受静脉激素治疗,激素敏感6例,无效11例,复发3例;随后对激素无效的11例及复发的3例行动脉硬化栓塞治疗,1例中途放弃治疗,8例有效,4例无效,1例复发;再对动脉栓塞治疗无效的4例及复发的1例加用长春新碱治疗,4例有效,1例并发弥散性血管内凝血死亡。本组激素治疗的敏感率为35.3%,但复发率为50%,动脉硬化栓塞术的有效率为61.5%。对激素及动脉硬化栓塞治疗无效的5例患儿使用长春新碱,有效率为80%。结论在新生儿KMS治疗中,糖皮质激素治疗抵抗常见。激素和动脉硬化栓塞联合治疗可作为新生儿KMS的一线治疗方案。上述治疗方法无效时,建议加用长春新碱。 Objective To summarize the clinical characteristics and therapeutic approaches of Ka- sabach-Merritt syndrome (KMS). Methods The data from 17 KMS patients that had been definitely diagnosed from December,2007 to January,2012 in our tertiary center were collected retrospectively. Results We de- scribed 17 patients,13 of whom were male and 4 of whom were female,with an age range of 17 hours to 28 days. Of the 17 cases,4 cases had hemangioma of internal organs,13 on the surface of the body. All of them had thrombocytopenia and coagulation dysfunction. Seventeen cases were initially treated with corticosteroids. The re- sponses were varied: excellent and rapid improvement ( n = 6 ), failure ( n = 11 ), recurrence ( n = 3 ). Then the cases of failure and recurrence accepted artery embolization: excellent and rapid improvement ( n = 8 ), failure ( n = 4 ), recurrence ( n = 1 ), with 1 giving up. At last, the cases resistant to artery embolization therapy accepted vincristine therapy. Four cases had rapid improvement, and 1 died from disseminated intravascular coagulation. In this study, a response rate to corticosteroids was 35. 3 %, and the recurrent rate was 50%. The response rate to ar- tery embolization was 61.5%. Five patients unresponsive to hormone therapy and artery embolism were treated with vincristine,and the effective rate was 80%. Conclusion In the therapy of neonatal KMS,the resistant to corticosteroids is common. Combinative therapy of corticosteroids with artery embolization is recommended as the first-line therapy. Vincristine is suggested as a therapy when there is resistance to the other therapy.
出处 《国际儿科学杂志》 2013年第4期426-429,共4页 International Journal of Pediatrics
关键词 KASABACH-MERRITT综合征 新生儿 激素 动脉硬化栓塞 长春新碱 Kasabach-Merritt syndrome Neonate Corticosteroids Artery embolization Vincristine
  • 相关文献

参考文献21

  • 1Kwok-Williams M, Perez Z, Squire R, et al. Radiotherapy for life- threatening mediastinal haemangioma with Kasabach-Merritt Syn- drome. Pediatr Blood Cancer,2007,49(5 ) :739-744.
  • 2雷红召,孙斌,刘大看,郭晓楠,马玉春,乔军波,董长宪.综合序贯疗法治疗Kasabach-Merritt综合征[J].中华医学杂志,2011,91(36):2538-2541. 被引量:12
  • 3Yoon HS,Lee JH, Moon HN, et al. Successful treatment of retroper- itoneal infantile hemangioendothelioma with Kasabach-Merritt syn- drome using steroid, a-interferon, and vincristine. J Pediatr Hematol Onco1,2009,31 ( 12 ) :952-954.
  • 4Hauer J,Graubner U, Konstantopoulos N, et al. Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach- Merritt phenomenon using four-drug regimen. Pediatr Blood Cancer, 2007,49(6) :852-854.
  • 5Hesselmann S, Micke O, Marquardt T, et al. Case report: Kasabach- Merritt syndrome: a review of the therapeutic option and a case report of successful treatment with radiotherapy and interferon alpha. Br J Radio1,2002,75 (890) : 180-184.
  • 6Kim T, Roh MR, Cho S, et al. Kasabach-Merritt syndrome arising from tufted angioma successfully treated with systemic corticoste- roid. Ann Dermatol,2010,22(4) :426-430.
  • 7Michaud AP,Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryn- goscope,2004,114 (7) : 1231-1236.
  • 8O'Regan GM, Irvine AD, Yao N, et al. Mediastinal and neck kaposi- form hemangioendothelioma: report of three cases. Pediatr Dermatol, 2009,26(3) :331-337.
  • 9Argentu LC,Bishop E, Cho KJ, et al. Complete resolution of life- threatening hemangioma by embolization and cortico-steroids. Plast Reconstr Surg, 1982,70 (6) :739-744.
  • 10Garcia-Monaco R, Giachetti A, Peralta O, et al. Kaposiform heman- gioendothelioma with Kasabach-Merritt phenomenon: Successful treatment with embolization and vincristine in two newborns. J Vasc Interv Radio1,2012,23 ( 3 ) :417-422.

二级参考文献13

  • 1董长宪,马玉春,李恭才,张连仲,郭会斌.尿素介入治疗面颌部重症海绵状血管瘤[J].中华整形外科杂志,2004,20(4):316-317. 被引量:20
  • 2Maguiness S,Guentber LKasabach-Merritt syndrome.J Cutan Med Surg,2002,6:335-339.
  • 3Frevel T,Rabe H,Uckert F,et al.Giant cavernous haemangioma with Kasabach-Merritt syndrome:a case report and review.Eur J Pediatr,2002,161:243-246.
  • 4Wananukul S,Nuchprayoon I,Seksarn P.Treatment of KasabachMerrittsyndrome:astepwiseregimenofprednisolone,dipyridamole,and interferon.Int J Dermatol,2003,42:741-748.
  • 5Abass K,Saad H,Kherala M,et al.Successful treatment of kasabach-merritt syndrome with vincristine and surgery:a case report and review of literature.Cases J,2008,1:9.
  • 6Hesselmann S,Micke O,Marquardt T,et al.Case report:Kasabach-Merritt syndrome:a review of the therapeutic option and a casereportof successfultreatmentwithradiotherapyand interferon alpha.Br J Radiol,2002,75:180-184.
  • 7Kim T,Roh MR,Cho S,et al.Kasabach-merritt syndrome arising fromtuftedangiomasuccessfullytreatedwithsystemic corticosteroid.Ann Dermatol,2010,22:426-430.
  • 8PhillipsWG,MarsdenJR.Kasabaeh-Merrittsyndrome exacerbated by platelet transfusion.J R Soc Med,1993,86:231-232.
  • 9董长宪,李恭才,张宪生,徐泉,高亚,苏宝山.碱性纤维母细胞生长因子在血管瘤及血管畸形中的表达[J].中华小儿外科杂志,1997,18(6):322-324. 被引量:14
  • 10董长宪,武宇红,马玉春,张连仲,刘大看,肖莉,雷红召.尿素与甲基强的松龙联合介入治疗颌面部重症血管瘤伴血小板减少[J].中华小儿外科杂志,2009,30(1):17-19. 被引量:7

共引文献28

同被引文献36

  • 1Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpun: report of a case [J]. Am J Dis Child, 1940, 59(5):1063-1070.
  • 2Hall GW. Kasabach Merritt syndrome: pathogenesis and management [J]. Br J Haematol, 2001, 112(4):851-862.
  • 3Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy [J]. Pediatrics, 2013, 131(1):99-108.
  • 4Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients [J]. J Am Acad Dermatol, 2000,42 (2 Pt 1):225-235.
  • 5Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma[J]. Plast Reconstr Surg, 1997, 100(6):1377-1386.
  • 6Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach- Merritt phenomenon in 107 referra/s [J]. J Pediatr, 2013, 162(1): 142-147.
  • 7Reenberger S, Boscolo E, Adini I, et al. Corticosteroid suppression of VEGFA in infantile hemangioma derived stem cells [J]. N Eng J Med, 2010, 36201):1005-1013.
  • 8Ryan C, Price V, John P, et al. Kasabach-Merritt phenomenon: a single center experience [J]. Eur J Haematol, 2010, 84(2):97-104.
  • 9Chao YH, Liang DC, Chen SH, et al. Interferon-alpha for alarming hemangiomas in infants: experience of a single institution[J]. Pediatr India, 2009, 51(4):469-473.
  • 10Holmes WJ, Mishra A, Gorst C, et al. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas[J]. J Hast Reconstr AES, 2011, 64(4):445-451.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部